The Role of Diabetes in the Onset and Development of Endothelial Dysfunction

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Abstract


The vascular endothelium performs many functions. It is a key regulator of vascular homeostasis, maintains a balance between vasodilation and vasoconstriction, inhibition and stimulation of smooth muscle cell migration and proliferation, fibrinolysis and thrombosis, and is involved to regulation of platelet adhesion and aggregation. Endothelial dysfunction (ED) plays the critical role in pathogenesis of diabetes mellitus (DM) vascular complications. The purpose of this review was to consider the mechanisms leading to the occurrence of ED in DM. The paper discusses current literature data concerning the role of hyperglycemia, oxidative stress, advanced glycation end products in endothelial alteration. A separate section is devoted to the particularities of the functioning of the antioxidant system and their significance in the development of ED in DM. The analysis of the literature allows to conclude that pathological activation of glucose utilization pathways causes damage of endothelial cells, which is accompanied by disorders of all their basic functions. Metabolic disorders in DM cause a pronounced imbalance of free radical processes and antioxidant defense, accompanied by oxidative stress of endotheliocytes, which contributes to the progression of ED and the development of vascular complications. Many aspects of multicomponent regulatory reactions in the pathogenesis of the development of ED in DM have not been sufficiently studied.


Full Text

About the authors

Era B. Popyhova

Saratov State Medical University named after V. I. Razumovsky

Email: PopyhovaEB@mail.ru
ORCID iD: 0000-0002-7662-4755
SPIN-code: 7810-3930

Russian Federation, 112 Bolshaya Kazachia st., Saratov, 410012, Russia

PhD, Senior Research Assistant of Central Scientific Research Laboratory

Tat’yana V. Stepanova

Saratov State Medical University named after V. I. Razumovsky

Email: cnil-sgmu@mail.ru
ORCID iD: 0000-0001-8439-8033
SPIN-code: 2744-9679

Russian Federation, 112 Bolshaya Kazachia st., Saratov, 410012, Russia

Junior Research Assistant of Central Scientific Research Laboratory

Dar’ya D. Lagutina

Saratov State Medical University named after V. I. Razumovsky

Email: cnil-sgmu@mail.ru
ORCID iD: 0000-0001-6219-3846
SPIN-code: 5786-2514

Russian Federation, 112 Bolshaya Kazachia st., Saratov, 410012, Russia

Assistant of Central Scientific Research Laboratory

Tat’yana S. Kiriyazi

Saratov Medical University "Reaviz"

Email: fev.6171@yandex.ru
ORCID iD: 0000-0001-6332-5249
SPIN-code: 5010-4870

Russian Federation, 10 Verhnii rinok st., Saratov, 410012, Russia

PhD, Associate Professor of Department of Biomedical Sciences

Alex’ey N. Ivanov

Saratov State Medical University named after V. I. Razumovsky

Author for correspondence.
Email: lex558452@gmail.com
ORCID iD: 0000-0003-4061-5221
SPIN-code: 3397-1840
Scopus Author ID: 56323761700
ResearcherId: L-5768-2015
Mendeley Profile: https://www.mendeley.com/profiles/alexey-ivanov16/

Russian Federation, 112 Bolshaya Kazachia st., Saratov, 410012, Russia

Dsc, Head of Central Scientific Research Laboratory

References

  • Куликов Д.А., Глазков А.А., Ковалева Ю.А., Балашова Н.В., Куликов А.В.Перспективы использования лазерной допплеровской флоуметрии в оценке кожной микроциркуляции крови при сахарном диабете.//Сахарный диабет.– 2017. – Т. 20. - №4 - 279-285. [Kulikov DA, Glazkov AA, Kovaleva YuA, Balashova NV, Kulikov AV. Prospects of Laser Doppler flowmetry application in assessment of skin microcirculation in diabetes. Diabetes Mellitus. 2017; 20(4):279-285.(In Russ)]
  • Гоженко А.И., Кузнецова А.С., Кузнецова Е.С., Быць Т.Н., Сусла А.Б. Эндотелиальная дисфункция в патогенезе осложнений сахарного диабета. Сообщение I. Эндотелиальная дисфункция: этиология, патогенез и методы диагностики.//Ендокринологія’- 2017- Т. 22. - № 2.- С.171-181. [Gozhenko AI, Kuznetsova HS, Kuznetsova KS, Byts TN, Susla AB. Endothelial dysfunction in the pathogenesis of diabetes complications The message I. Endothelial dysfunction: etiology, pathogenesis and diagnostic methods. Endokrynologia. 2017;22(2):171-181. (In Russ)]
  • Васина Л. В., Петрищев Н. Н., Власов Т.Д. Эндотелиальная дисфункция и ее основные маркеры // Регионарное кровообращение и микроциркуляция. – 2017. – Т. 16 - № 1 – С. 4–15. [Vasina LV, Petrishchev NN, Vlasov TD. Markers of endothelial dysfunction.Regional blood circulation and microcirculation. 2017; 16(1):4–15. (In Russ.)]. doi: 10.24884/1682-6655-2017-16-1-4-15.
  • Васина Л.В., ВласовТ.Д., Петрищев Н.Н. Функциональная гетерогенность эндотелия (обзор).//Артериальная гипертензия. – 2017.– Т. 23 - № 2. – С. 88–102. [Vasina LV, Vlasov TD, Petrishchev NN. Functional heterogeneity of the endothelium (the review). Arterial Hypertension. 2017; 23(2):88–102. (In Russ.)].doi: 10.18705/1607-419X-2017-23-2-88-102.
  • Мельникова Ю.С., Макарова Т.П. Эндотелиальная дисфункция как центральное звено патогенеза хронических болезней.// Казанский медицинский журнал. – 2015. – Т. 96 - № 4. –C. 659–665. [Mel’nikova JuS, Makarova TP. Endothelial dysfunction as the key link of chronic diseases pathogenesis. Kazan Medical Journal. 2015; 96(4):659–665. (In Russ.)]. doi: 10.17750/KMJ2015-659.
  • Власов Т. Д., Нестерович И. И., Шиманьски Д. А. Эндотелиальная дисфункция: от частного к общему. Возврат к «старой парадигме»?// Регионарное кровообращение и микроциркуляция. - 2019. –Т.18 - №2. – С. 19–27. [Vlasov TD, Nesterovich II, Shimanski DA. Endothelial dysfunction: from the particular to the general. Return to the «Old Paradigm»? Regional hemodynamics and microcirculation. 2019; 18(2): 19–27. (In Russ.)] doi: 10.24884/1682-6655-2019-18-2-19-27.
  • Степанова Т.В., Иванов А.Н., Терешкина Н.Е., Попыхова Э.Б., Лагутина Д.Д. Маркеры эндотелиальной дисфункции: патогенетическая роль и диагностическое значение (обзор литературы) // Клиническая лабораторная диагностика. – 2019. – Т. 64. - № 1. - С. 34-41. [Stepanova TV, Ivanov AN, Tereshkina NE, Popyhova EB, Lagutina DD. Markers of endothelial dysfunction: pathogenetic role and diagnostic significance. Klinicheskaia laboratornaia diagnostika. 2019: 64(1): 34-41. (In Russ.)]
  • Torimoto K, Okada Y, Tanaka Y. Type 2 Diabetes and Vascular Endothelial Dysfunction. J UOEH. 2018; 40(1):65–75. doi: 10.7888/juoeh.40.65.
  • Sena CM, Pereira AM, Seiça R. Endothelial dysfunction — A major mediator of diabetic vascular disease. Biochimica et Biophysica Acta. 2013; 1832: 2216–2231.
  • Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018; 17(1):121. doi: 10.1186/s12933-018-0763-3.
  • Zhang H, Dellsperger KC, Zhang C. The link between metabolic abnormalities and endothelial dysfunction in type 2 diabetes: an update. Basic Res Cardiol. 2012; 107(1):237. doi: 10.1007/s00395-011-0237-1.
  • Иванов А.Н., Пучиньян Д.М., Норкин И.А. Барьерная функция эндотелия, механизмы ее регуляции и нарушения Успехи физиологических наук. 2015. – Т. 46. - № 2. - С. 72-96. [Ivanov AN, Puchinyan DM, Norkin IA. Vascular Endothelial Barrier Function. Uspekhi fiziologicheskikh nauk. 2015; 46(2) 72-96. (In Russ.)]
  • Sena CM, Carrilho F, Seiç RM. Endothelial Dysfunction in Type 2 Diabetes: Targeting Inflammation In: Lenasi H, editor. Endothelial Dysfunction – Old Concepts and New Challenges. London:Intechopen. 2018; p. 231-249. doi: 10.5772/intechopen.76994.
  • Sena CM, Leandro A, Azul L, Seiça R, Perry G. Vascular Oxidative Stress: Impact and Therapeutic Approaches. Front. Physiol. 2018; 9:1668.doi: 10.3389/fphys.2018.01668.
  • Roberts AC, Porter KE. Cellular and molecular mechanisms of endothelial dysfunction in diabetes. Diab Vasc Dis Res. 2013; 10(6):472–482. doi: 10.1177/1479164113500680.
  • Попыхова Э.Б., Иванов А.Н., Степанова Т.В., Пронина Е.А., Лагутина Д.Д. Взаимосвязь нарушений углеводного обмена и маркеров дисфункции эндотелия у животных с абсолютной недостаточностью инсулина при биостимуляции аутотрансплантацией кожного лоскута.//Саратовский научно-медицинский журнал.-2019. – Т. 15. - №2 – С. 379–382. [Popykhova EB, Ivanov AN, Stepanova TV, Pronina EA, Lagutina DD. The relation of carbohydrate metabolism disorders and markers of endothelial dysfunction in animals with absolute insulin deficiency at biostimulation by autotransplantation of the skin flap. Saratov Journal of Medical Scientific Research 2019; 15 (2): 379–382 (In Russ.)]
  • Лебедева Н.О., Викулова О.К. Маркеры доклинической диагностики диабетической нефропатии у пациентов с сахарным диабетом 1 типа.//Сахарный диабет. - 2012. – Т.2 - С.38–45. [Lebedeva NO, Vikulova OK. Pre-clinical markers for diagnosis of diabetic nephropathy in patients with type 1 diabetes mellitus. Diabetes Mellitus. 2012; (2):38–45. (In Russ.)]
  • Шестакова М.В. Сахарный диабет и хроническая болезнь почек: возможности прогнозирования, ранней диагностики и нефропротекции в XXI веке.// Терапевтический архив. - 2016.- №6. -С. 84-88. [Shestakov MV. Diabetes mellitus and chronic kidney disease: Possibilities of prediction, early diagnosis, andnephroprotection in the 21st century. Terapevticheskij arxiv.2016; (6): 84-88. (In Russ.)] doi: 10.17116/terarkh201688684-88.
  • Занозина О.В., Боровков Н.Н., Щербатюк Т.Г. Свободно-радикальное окисление при сахарном диабете 2-го типа: источники образования, составляющие, патогенетические механизмы токсичности. //Соврем. технол. в мед. - 2010.- № - 3.- С.104-112. [Zanozina OV, Borovkov NN, Sherbatyuk TG. Free-radical oxidation at a diabetes mellitus of the 2nd type: sources of formation, components, pathogenetic mechanisms of toxicity.//Modern Technologies in Medicine. 2010;(3): 104-112 (In Russ.)]
  • Gero D. Hyperglycemia-Induced Endothelial Dysfunction. In: Lenasi H, editor. Endothelial Dysfunction – Old Concepts and New Challenges. London: Intechopen. 2018; 179-210. doi: 10.5772/intechopen.76994.
  • Goldberg HJ, Whiteside CI, Fantus IG. The hexosamine pathway regulates the plasminogen activator inhibitor-1 gene promoter and sp1 transcriptional activation through protein kinase С-beta I and -delta. J Biol. Chem. 2002; 277: 33833–33841.
  • Худякова Н.В., Иванов Н.В., Пчелин И.Ю., Шишкин А.Н., Ворохобина Н.В., Байрашева В.К., Василькова О.Н. Диабетическая нейропатия: молекулярные механизмы развития и возможности патогенетической терапии.// Juvenis Scientia. - 2019. - № 4.- С.8-12. [Hudiakova NV, Ivanov NV, Pchelin IYu, Shishkin AN, Vorokhobina NV, Bayrasheva VK, Vasilkova VN. Diabetic neuropathy: molecular mechanisms of development and possibilities for pathogenetic therapy. 2019; 4; С.8-12. (In Russ.)] doi: 10.32415/jscientia.2019.04.02.
  • Заводник И.Б., Дремза И.К., Лапшина Е.А., Чещевик В.Т. Сахарный диабет: метаболические эффекты и окислительный стресс.// Биологические мембраны. - 2011. - том 28 - №2 - С. 83–94. [Zavodnik IB, Dremza IK, Lapshina EA, Cheshchevik VT. Diabetes Mellitus: Metabolic Effects and Oxidative Stress. Biochemistry (Moscow) Supplement. Series A: Membrane and Cell Biology. 2011; 28, (2): 83–94]. (In Russ.)]
  • Тюренков И.Н., Воронков А.В., Слиецанс А.А., Доркина Е.Г., Снигур Г.Л. Антиоксидантная терапия эндотелиальной дисфункци.//Обзоры по клинической фармакологии и лекарственной терапии 2013. - Т.11. - №1. - С.14-25. [Tyurenkov IN, Voronkov AV, Slieczans AA, Dorkina EG, Snigur GL. Antioksidantnayaterapiyae`ndotelial`nojdisfunkci. Obzory` poklinicheskoj farmakologi i lekarstvennoj terapii. 2013; 11 (1): 14-25. (In Russ.)]
  • Куликов В.Ю. Роль окислительного стресса в регуляции метаболической активности внеклеточного матрикса соединительной ткани (обзор).//J Siberian Med Scien. - 2009. - № 4. -С. 1-16. [Kulikov VU. The metabolic activity role of oxidixing stress regulation in non-cellular matrix connective tissue (review). J Siberian Med Scien. 2009; 4: 1-16. (In Russ.)]
  • Leopold JA, Loscalzo J. Oxidative enzymopathies and vascular disease. Arterioscler.Thromb.Vasc.Biol. 2005; 25: 1332-1340.
  • MuzykantovVR. Targeting of superoxide dismutase and catalase to vascular endothelium. J Control. Release. 2001; 71:1-21.
  • Zhang Y, Handy DE, Loscalzo J. Adenosine-dependent induction of glutathione peroxidase 1 in human primary endothelial cells and protection against oxidative stress. Circ. Res. 2005; 96: 831-837.
  • Lewis P, Stefanovic N, Pete J, Calkin AC, Giunti S, Thallas-Bonke V, Jandeleit-Dahm KA, Allen TJ, Kola I, Cooper ME, de Haan JB. Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation.2007; 115: 2178-2187.
  • Weiss N, Zhang YY, Heydrick S, Bierl C, Loscalzo J. Overexpression of cellular glutathione peroxidase rescues homocyst(e)ine-induced endothelial dysfunction. Proc. Natl. Acad. Sci. U. S. A. 2001; 98: 12503-12508.
  • Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu. Rev. Pharmacol. Toxicol. 2005; 45: 51-88.
  • Maulik. N, Das DK. Emerging potential of thioredoxin and thioredoxin interacting proteins in various disease conditions. Biochim. Biophys. Acta. 2008; 1780: 1368-1382.
  • Marcantoni E, Di Francesco L, Dovizio M, Bruno A, Patrignani P. Novel insights into the vasoprotective role of heme oxygenase-1. Int. J Hypertens. 2012; 2012:127910. doi: 10.1155/2012/127910.
  • Боровкова Е.И., Антипова Н.В., КорнеенкоТ.В., Шахпаронов М.И., Боровков И.М. Параоксоназа: универсальный фактор антиоксидантной защиты организма человека.//Вестник РАМН. - 2017. – Т.72. - №1 – С.5–10. [Borovkova EI, Antipova NV, Korneenko TV, Shakhparonov MI, Borovkov IM. Paraoxonase: The Universal Factor of Antioxidant Defense in Human Body. Annals of the Russian Academy of Medical Sciences.2017; 72(1):5–10. (In Russ.)]doi: 10.15690/vramn764.
  • Kulka M. A review of paraoxonase 1 properties and diagnostic applications. Polish. J Veterinary Sciences. 2016; 19(1):225–232. doi: 10.1515/pjvs-2016-0028.
  • Rajković GM, Rumora L, Barišić K. The paraoxonase 1, 2 and 3 in humans. Biochem Med (Zagreb). 2011; 21(2):122–30. doi: 10.11613/bm.2011.020.
  • Rozenberg O, Shih DM, Aviram M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis.2005; 181: 9-18.
  • Altenhofer S, Witte I, Teiber JF. One enzyme, two functions: PON2 prevents mitochondrial superoxide formation and apoptosis independent from its lactonase activity. J Biol Chem. 2010; 285(32):24398–24403. doi: 10.1074/jbc.m110.118604.
  • Devarajan A, Bourquard N, Hama S. Paraoxonase 2 deficiency alters mitochondrial function and exacerbates the development of atherosclerosis. Antioxid Redox Signal. 2011;14(3):341–351. doi: 10.1089/ars.2010.3430.
  • Giordano G, Cole TB, Furlong CE, Costa LG. Paraoxonase 2 (PON2) in the mouse central nervous system: a neuroprotective role? Toxicol Appl Pharmacol. 2011; 256(3):369–378. doi: 10.1016/j. taap.2011.02.014
  • Bourquard N, Ng CJ, Reddy ST. Impaired hepatic insulin signalling in PON2-deficient mice: a novel role for the PON2/ apoE axis on the macrophage inflammatory response. Biochem J. 2011; 436(1):91–100. doi: 10.1042/bj20101891.
  • Higgins GC, Beart PM, Shin YS. Oxidative stress: emerging mitochondrial and cellular themes and variations in neuronal injury. J Alzheimers Dis. 2010; 20(2): S453–473. doi: 10.3233/ JAD-2010-100321.
  • Dhananjayan R, Koundinya KSS, Malati T, Kutala VK. Endothelial Dysfunction in Type 2 Diabetes Mellitus. Indian J Clin Biochem. 2016; 31(4): 372–379. doi: 10.1007/s12291-015-0516-y.
  • Худякова Н.В., Пчелин И.Ю., Шишкин А.Н. Взаимосвязь гипергомоцистеинемии с гематологическими нарушениями и сердечно-сосудистыми осложнениями при диабетической нефропатии.//Научный аспект.- 2015. - № 3(2). - С. 271-81.[Hudyakova NV, Pchelin IYu, Shishkin AN. Vzaimosvyaz' gipergomotsisteinemii s gematologicheskimi narusheniyami i serdechno-sosudistymi oslozhneniyami pri diabetichesko inefropatii. Nauchnyi aspekt.2015; 3(2):271-81. (In Russ)]
  • Jenkins AJ, Joglekar MV, Hardikar AA, Keech AC, O’Neal DN, Januszewski AS. Biomarkers in Diabetic Retinopathy. Rev Diabet Stud. 2015;12(1–2):159–195. doi: 10.1900/RDS.2015.12.159.
  • Stirban A, Gawlowski T, Roden M. Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms. Mol Metab. 2013;3(2):94-108. doi: 10.1016/j.molmet.2013.11.006.
  • Ahmad S, Siddiqui Z, Rehman S, Khan MY, Khan H, Khanum S, Alouffi S, Saeed M. A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure. Curr Vasc Pharmacol. 2017;15(4):352-364. doi: 10.2174/1570161115666170327162639.

Statistics

Views

Abstract - 34

PDF (Russian) - 0

PlumX

Dimensions


Copyright (c) Popyhova E.B., Stepanova T.V., Lagutina D.D., Kiriyazi T.S., Ivanov A.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies